Organon (OGN) is back in focus after presenting a post hoc pooled analysis of its Phase 3 ADORING 1 and 2 trials for VTAMA cream at the 2026 American Academy of Dermatology meeting.
See our latest analysis for Organon.
Despite the upbeat VTAMA data, Organon’s 1-day share price return of 4.87% and 30-day share price return of 7.77% sit within a much weaker pattern. The 90-day share price return of 25.03% and 1-year total shareholder return of 51.21% point to fading momentum overall.
If this dermatology update has you thinking about where growth in healthcare might come from next, it could be worth scanning for other ideas in 37 healthcare AI stocks
With Organon trading at US$6.05, a value score of 5, an intrinsic discount flag and a price target of US$9.00, you have to ask whether this weakness is a genuine mispricing or already reflects realistic growth expectations.
Most Popular Narrative: 32.8% Undervalued
With Organon last closing at $6.05 against a narrative fair value of $9.00, the widely followed view frames this as a sizeable valuation gap built on detailed growth, margin and risk work.
The biosimilars portfolio is outperforming expectations, underpinned by accelerating adoption (e.g., Hadlima's growth, new launches like Tofidence, and a strong pipeline including Henlius denosumab), providing a sustainable pathway to top-line expansion while benefiting from industry-wide momentum toward biosimilars as key biologics lose exclusivity.
Curious how modest revenue assumptions, fatter margins and a compressed future P/E all combine into that $9.00 fair value tag? The narrative leans heavily on one revenue line, a step up in profitability and a discount rate that quietly shapes the outcome. The full breakdown shows exactly how those moving parts stack together.
Result: Fair Value of $9.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if mature, off-patent products face faster erosion or if restructuring and cost savings take longer to show up.
Find out about the key risks to this Organon narrative.
Next Steps
If the outlook for Organon seems finely balanced between optimism and concern, do not wait for a consensus. Instead, review the 3 key rewards and 3 important warning signs for yourself with 3 key rewards and 3 important warning signs
Ready for more investment ideas?
If Organon has caught your attention, do not stop there. Use the time you have today to hunt for other opportunities before the crowd notices them.
- Scan for potential value ideas by reviewing 62 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial profile.
- Strengthen the income side of your portfolio by checking out 13 dividend fortresses that focus on higher yields supported by underlying cash flows.
- Prioritise resilience by focusing on 68 resilient stocks with low risk scores that score well on financial stability and lower overall risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com